EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dexrazoxane does not mitigate early vascular toxicity induced by doxorubicin in mice

Matthias Bosman iD, Dustin N Krüger, Kasper Favere, Guido R Y De Meyer iD, Constantijn Franssen, Emeline M Van Craenenbroeck, Pieter-Jan Guns iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0294848 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Matthias Bosman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Physiopharmacology, Faculty of Medicine and Health Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Campus Drie…. Hauptthemen laut MEDLINE: Dexrazoxane. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fund for Scientific Research, FWO Flanders, Foundation against Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Apart from cardiotoxicity, the chemotherapeutic agent doxorubicin (DOX) provokes acute and long-term vascular toxicity. Dexrazoxane (DEXRA) is an effective drug for treatment of DOX-induced cardiotoxicity, yet it remains currently unknown whether DEXRA prevents vascular toxicity associated with DOX. Accordingly, the present study aimed to evaluate the protective potential of DEXRA against DOX-related vascular toxicity in a previously-established in vivo and ex vivo model of vascular dysfunction induced by 16 hour (h) DOX exposure. Vascular function was evaluated in the thoracic aorta in organ baths, 16h after administration of DOX (4 mg/kg) or DOX with DEXRA (40 mg/kg) to male C57BL6/J mice. In parallel, vascular reactivity was evaluated after ex vivo incubation (16h) of murine aortic segments with DOX (1 μM) or DOX with DEXRA (10 μM). In both in vivo and ex vivo experiments, DOX impaired acetylcholine-stimulated endothelium-dependent vasodilation. In the ex vivo setting, DOX additionally attenuated phenylephrine-elicited vascular smooth muscle cell (VSMC) contraction. Importantly, DEXRA failed to prevent DOX-induced endothelial dysfunction and hypocontraction. Furthermore, RT-qPCR and Western blotting showed that DOX decreased the protein levels of topoisomerase-IIβ (TOP-IIβ), a key target of DEXRA, in the heart, but not in the aorta. Additionally, the effect of N-acetylcysteine (NAC, 10 μM), a reactive oxygen species (ROS) scavenger, was evaluated ex vivo . NAC did not prevent DOX-induced impairment of acetylcholine-stimulated vasodilation. In conclusion, our results show that DEXRA fails to prevent vascular toxicity resulting from 16h DOX treatment. This may relate to DOX provoking vascular toxicity in a ROS- and TOP-IIβ-independent way, at least in the evaluated acute setting. However, it is important to mention that these findings only apply to the acute (16h) treatment period, and further research is warranted to delineate the therapeutic potential of DEXRA against vascular toxicity associated with longer-term repetitive DOX dosing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexrazoxaneMiceAnimalsMaleReactive Oxygen SpeciesCardiotoxicityAcetylcholineDoxorubicinMice, Inbred C57BLMyocytes, CardiacAntibiotics, Antineoplastic

Substanzen

DexrazoxaneReactive Oxygen SpeciesAcetylcholineDoxorubicinAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • Laboratory of Physiopharmacology, Faculty of Medicine and Health Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Campus Drie Eiken, University of Antwerp, Antwerp, Belgium.
  • Research Group Cardiovascular Diseases, GENCOR, University of Antwerp, Antwerp, Belgium.
  • Department of Cardiology, Antwerp University Hospital (UZA), Edegem, Belgium.

ORCID-Profile: Matthias Bosman, Guido R Y De Meyer, Pieter-Jan Guns

Förderung

  • Fund for Scientific Research
  • FWO Flanders
  • Foundation against Cancer
  • DOCPRO4 grant of the Research Council of the University of Antwerp
  • European Union's Horizon 2020 Research and Innovation Program

Zitieren

APA

Bosman, M., Krüger, D. N., Favere, K., De Meyer, G. R. Y., Franssen, C., Van Craenenbroeck, E. M., & Guns, P. J. (2023). Dexrazoxane does not mitigate early vascular toxicity induced by doxorubicin in mice. PLOS ONE. https://doi.org/10.1371/journal.pone.0294848

Vancouver

Bosman M, Krüger DN, Favere K, De Meyer GRY, Franssen C, Van Craenenbroeck EM, et al. Dexrazoxane does not mitigate early vascular toxicity induced by doxorubicin in mice. PLOS ONE. 2023. doi:10.1371/journal.pone.0294848

BibTeX
@article{Bosman2023,
  author = {Bosman, Matthias and Krüger, Dustin N and Favere, Kasper and De Meyer, Guido R Y and Franssen, Constantijn and Van Craenenbroeck, Emeline M and Guns, Pieter-Jan},
  title = {Dexrazoxane does not mitigate early vascular toxicity induced by doxorubicin in mice},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0294848}
}
Kostenlos starten →